Bioaffinity Technologies Warrant Stock Analysis
| BIAFW Stock | USD 0.57 0.13 18.57% |
bioAffinity Technologies Warrant is overvalued with Real Value of 0.55 and Hype Value of 0.57. The main objective of BioAffinity Technologies stock analysis is to determine its intrinsic value, which is an estimate of what bioAffinity Technologies Warrant is worth, separate from its market price. There are two main types of BioAffinity Technologies' stock analysis: fundamental analysis and technical analysis.
The BioAffinity Technologies stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. BioAffinity Technologies is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. BioAffinity Stock trading window is adjusted to America/New York timezone.
BioAffinity |
BioAffinity Stock Analysis Notes
The company had not issued any dividends in recent years. bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company was founded in 2014 and is based in San Antonio, Texas. Bioaffinity Technologies operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. For more info on bioAffinity Technologies Warrant please contact the company at 210 698 5334 or go to https://www.bioaffinitytech.com.BioAffinity Technologies Investment Alerts
| BioAffinity Technologies generated a negative expected return over the last 90 days | |
| BioAffinity Technologies has high historical volatility and very poor performance | |
| BioAffinity Technologies has some characteristics of a very speculative penny stock | |
| BioAffinity Technologies has a very high chance of going through financial distress in the upcoming years | |
| bioAffinity Technologies Warrant has accumulated 1.58 M in total debt. BioAffinity Technologies has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about BioAffinity Technologies' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the revenue of 2.53 M. Net Loss for the year was (7.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| bioAffinity Technologies Warrant has accumulated about 214.4 K in cash with (6.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08. | |
| Latest headline from businesswire.com: Acquisition by Zannes Timothy P of 3619 shares of BioAffinity Technologies subject to Rule 16b-3 |
BioAffinity Profitablity
The company has Profit Margin (PM) of (1.19) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.87) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.87.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.33) | (1.39) | |
| Return On Capital Employed | (1.33) | (1.27) | |
| Return On Assets | (0.97) | (1.01) | |
| Return On Equity | (1.63) | (1.55) |
Management Efficiency
The company has return on total asset (ROA) of (0.6978) % which means that it has lost $0.6978 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.5152) %, meaning that it generated substantial loss on money invested by shareholders. BioAffinity Technologies' management efficiency ratios could be used to measure how well BioAffinity Technologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.39 in 2024. Return On Capital Employed is likely to climb to -1.27 in 2024. At this time, BioAffinity Technologies' Non Current Assets Total are fairly stable compared to the past year. Total Current Assets is likely to climb to about 4 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 10 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.56 | 0.58 | |
| Tangible Book Value Per Share | 0.30 | 0.31 | |
| Enterprise Value Over EBITDA | (1.52) | (1.60) | |
| Price Book Value Ratio | 2.65 | 2.78 | |
| Enterprise Value Multiple | (1.52) | (1.60) | |
| Price Fair Value | 2.65 | 2.78 | |
| Enterprise Value | 11.6 M | 11 M |
The strategic decisions made by BioAffinity Technologies management significantly impact its financial stability and market performance. Evaluating these factors helps determine whether the stock is a worthwhile investment.
Operating Margin (0.87) | Profit Margin (1.19) | Beta 3.124 | Return On Assets (0.70) | Return On Equity (1.52) |
Technical Drivers
As of the 23rd of November, BioAffinity Technologies shows the Coefficient Of Variation of (3,822), risk adjusted performance of (0.01), and Standard Deviation of 17.07. BioAffinity Technologies technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm BioAffinity Technologies variance and potential upside to decide if BioAffinity Technologies is priced correctly, providing market reflects its regular price of 0.57 per share. As BioAffinity Technologies is a penny stock we also strongly suggest to validate its jensen alpha numbers.BioAffinity Technologies Price Movement Analysis
The output start index for this execution was two with a total number of output elements of fifty-nine. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. BioAffinity Technologies middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for BioAffinity Technologies. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
BioAffinity Technologies Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioAffinity Technologies insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioAffinity Technologies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioAffinity Technologies insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Diamond Stuart over a month ago Acquisition by Diamond Stuart of 10245 shares of BioAffinity Technologies at 1.83 subject to Rule 16b-3 | ||
Steven Girgenti over two months ago Acquisition by Steven Girgenti of 7657 shares of BioAffinity Technologies at 4.2 subject to Rule 16b-3 | ||
Zannes Maria over two months ago Disposition of tradable shares by Zannes Maria of BioAffinity Technologies subject to Rule 16b-3 | ||
Knight Peter S over two months ago Disposition of 7142 shares by Knight Peter S of BioAffinity Technologies at 4.2 subject to Rule 16b-3 | ||
Meghji Mohsin Y over six months ago Acquisition by Meghji Mohsin Y of 9920 shares of BioAffinity Technologies at 1.89 subject to Rule 16b-3 | ||
Dougherty Michael Philip over six months ago Insider Trading | ||
Steven Girgenti over six months ago Acquisition by Steven Girgenti of 156602 shares of BioAffinity Technologies at 4.2 subject to Rule 16b-3 |
BioAffinity Technologies Predictive Daily Indicators
BioAffinity Technologies intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BioAffinity Technologies stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
BioAffinity Technologies Forecast Models
BioAffinity Technologies' time-series forecasting models are one of many BioAffinity Technologies' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioAffinity Technologies' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About BioAffinity Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how BioAffinity Technologies prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling BioAffinity shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as BioAffinity Technologies. By using and applying BioAffinity Stock analysis, traders can create a robust methodology for identifying BioAffinity entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (3.13) | (3.28) | |
| Operating Profit Margin | (3.15) | (3.31) | |
| Net Loss | (3.13) | (3.29) | |
| Gross Profit Margin | 0.31 | 0.30 |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding BioAffinity Technologies to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Insider Screener Now
Insider ScreenerFind insiders across different sectors to evaluate their impact on performance |
| All Next | Launch Module |
Additional Tools for BioAffinity Stock Analysis
When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.